MSMR. 2021 Mar;28(3):2-8.
Laboratory-based influenza surveillance was conducted in the 2019-2020 influenza season among Department of Defense (DoD) beneficiaries through the DoD Global Respiratory Pathogen Surveillance Program (DoDGRS). Sentinel and participating sites submitted 28,176 specimens for clinical diagnostic testing. A total of 5,529 influenza-positive cases were identified. Starting at surveillance week 45 (3-9 November 2019), influenza B was the predominant influenza type, followed by high activity of influenza A(H1N1)pdm09 three weeks thereafter. Both influenza B and influenza A(H1N1)pdm09 were then highly co-circulated through surveillance week 13 (22-28 March 2020). End-of-season influenza vaccine effectiveness (VE) was estimated using a test-negative case-control study design. The adjusted end-of-season VE for all beneficiaries, regardless of influenza type or subtype, was 46% (95% confidence interval: 40%-52%). The influenza vaccine was moderately effective against influenza viruses during the 2019-2020 influenza season.
在 2019-2020 流感季，通过国防部全球呼吸道病原体监测计划（DoDGRS），对国防部受益人进行了基于实验室的流感监测。哨点和参与机构提交了 28176 份用于临床诊断检测的标本。共发现 5529 例流感阳性病例。从监测第 45 周（2019 年 11 月 3 日至 9 日）开始，乙型流感成为主要流感类型，三周后甲型 H1N1pdm09 流感的活跃度较高。此后，乙型流感和甲型 H1N1pdm09 一直高度共同流行，直到监测第 13 周（2020 年 3 月 22 日至 28 日）。使用病例对照检验阴性设计估计了季节性流感疫苗的期末有效性。无论流感类型或亚型如何，所有受益人的期末调整疫苗有效性为 46%（95%置信区间：40%-52%）。在 2019-2020 流感季，流感疫苗对流感病毒的有效性为中等。
